RxDoctor Payments Data

Eugene Dawson, DO

Cardiovascular Disease · Indian Land, SCNPI 1346282555

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $145, 4.4 times the $33 reported in 2021. That places this record below the midpoint for cardiovascular disease clinicians in SC, where the typical reported total is $3,855.

$376in general payments, 2019–2025

Across 19 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Irhythm Technologies, Inc.$86
  • Abbott$61
  • Boehringer Ingelheim$59
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$53
  • Medtronic$33
  • Scpharmaceuticals Inc.$24
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$376 in reported general payments places this provider in the 10th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina →

Medicare billing

Part B allowed, 2024
$151,164
Medicare patients
982
Services billed
2,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$222,974
XareltoRivaroxaban49$63,799
Repatha SureclickEvolocumab15$9,956
Metoprolol Succinate201$3,001
Verapamil SrVerapamil Hcl17$1,826
Diltiazem 24hr Er (Cd)Diltiazem Hcl54$1,279
Losartan Potassium64$1,032
Flecainide Acetate17$971
Valsartan11$920
Atorvastatin Calcium81$720
Digoxin35$710
ClopidogrelClopidogrel Bisulfate25$492
Rosuvastatin Calcium31$474
Carvedilol59$462
Amlodipine Besylate88$453

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Indian Land

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →